Go Pro
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free IMMX Stock Alerts

Immix Biopharma (IMMX) Financials

Immix Biopharma logo
$10.38 -0.30 (-2.77%)
As of 11:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Immix Biopharma

Annual Income Statements for Immix Biopharma

This table shows Immix Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.21 -24 -8.23 -15 -22 -29
Consolidated Net Income / (Loss)		 -1.15 -24 -8.23 -16 -22 -29
Net Income / (Loss) Continuing Operations		 -2.28 -24 -8.23 -16 -22 -29
Total Pre-Tax Income 		-1.13 -24 -8.22 -16 -22 -29
Total Operating Income		 -0.45 -1.35 -8.22 -16 -23 -30
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 0.91 1.35 8.22 16 23 30
Selling, General & Admin Expense		 0.21 1.23 4.02 7.41 11 14
Research & Development Expense		 0.25 0.13 4.20 8.74 11 16
Total Other Income / (Expense), net		 -1.35 -23 -0.00 0.57 1.02 0.56
Interest & Investment Income		 - - 0.00 0.57 1.02 0.56
Income Tax Expense		 0.02 0.01 0.01 0.03 0.04 0.04
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - 0.00 -0.17 -0.08 0.00
Basic Earnings per Share		 ($0.34) ($6.64) ($0.59) ($0.89) ($0.76) ($0.89)
Weighted Average Basic Shares Outstanding		 3.38M 3.67M 13.89M 17.34M 28.29M 32.97M
Diluted Earnings per Share		 ($0.34) - ($0.59) ($0.89) ($0.76) ($0.89)
Weighted Average Diluted Shares Outstanding		 3.38M 13.86M 13.89M 17.34M 28.29M 32.97M
Weighted Average Basic & Diluted Shares Outstanding		 3.38M 13.86M 13.90M 26.40M 27.72M 52.96M

Quarterly Income Statements for Immix Biopharma

This table shows Immix Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.28 -5.09 -5.26 -4.39 -7.15 -4.81 -4.53 -6.62 -7.59 -11 -10
Consolidated Net Income / (Loss)		 -4.34 -5.16 -5.33 -4.41 -7.15 -4.81 -4.54 -6.62 -7.59 -11 -10
Net Income / (Loss) Continuing Operations		 -4.34 -5.16 -5.33 -4.41 -7.15 -4.81 -4.54 -6.62 -7.59 -11 -10
Total Pre-Tax Income 		-4.34 -5.15 -5.32 -4.40 -7.14 -4.80 -4.53 -6.61 -7.58 -11 -10
Total Operating Income		 -4.52 -5.38 -5.59 -4.70 -7.39 -4.99 -4.68 -6.72 -7.66 -11 -11
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 4.52 5.38 5.59 4.70 7.39 4.99 4.68 6.72 7.66 11 11
Selling, General & Admin Expense		 2.42 2.28 2.34 2.48 2.95 3.61 2.71 2.75 3.08 5.17 4.82
Research & Development Expense		 2.11 3.10 3.25 2.22 4.45 1.37 1.98 3.97 4.58 5.73 5.98
Total Other Income / (Expense), net		 0.19 0.23 0.27 0.31 0.26 0.19 0.15 0.10 0.08 0.22 0.72
Interest & Investment Income		 0.19 0.23 0.27 0.31 0.26 0.19 0.15 0.10 0.08 0.22 0.72
Income Tax Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - - - -0.02 - - - -0.05
Basic Earnings per Share		 ($0.23) ($0.24) ($0.22) ($0.15) ($0.24) ($0.15) ($0.15) ($0.22) ($0.24) ($0.28) ($0.18)
Weighted Average Basic Shares Outstanding		 18.58M 17.34M 23.44M 28.79M 29.42M 28.29M 29.70M 29.98M 31.93M 32.97M 55.37M
Diluted Earnings per Share		 ($0.23) ($0.24) ($0.22) ($0.15) ($0.24) ($0.15) ($0.15) ($0.22) ($0.24) ($0.28) ($0.18)
Weighted Average Diluted Shares Outstanding		 18.58M 17.34M 23.44M 28.79M 29.42M 28.29M 29.70M 29.98M 31.93M 32.97M 55.37M
Weighted Average Basic & Diluted Shares Outstanding		 19.87M 26.40M 26.41M 27.45M 27.51M 27.72M 27.88M 28.83M 33.58M 52.96M 54.41M

Annual Cash Flow Statements for Immix Biopharma

This table details how cash moves in and out of Immix Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.34 17 -4.21 4.07 0.17 76
Net Cash From Operating Activities		 -0.40 -1.59 -7.41 -11 -15 -24
Net Cash From Continuing Operating Activities		 -0.40 -1.59 -7.41 -11 -15 -24
Net Income / (Loss) Continuing Operations		 -1.15 -24 -8.23 -16 -22 -29
Consolidated Net Income / (Loss)		 -1.15 -24 -8.23 -16 -22 -29
Depreciation Expense		 0.00 0.00 0.00 0.01 0.03 0.25
Amortization Expense		 0.00 0.06 - 0.00 0.08 0.12
Non-Cash Adjustments To Reconcile Net Income		 0.58 23 0.62 2.57 3.02 2.44
Changes in Operating Assets and Liabilities, net		 0.17 -0.39 0.20 1.65 3.97 2.70
Net Cash From Investing Activities		 0.00 -0.00 0.00 -0.05 -1.18 -7.21
Net Cash From Continuing Investing Activities		 0.00 -0.00 0.00 -0.05 -1.18 -7.21
Purchase of Property, Plant & Equipment		 0.00 -0.00 0.00 -0.05 -1.18 -0.73
Purchase of Investments		 - - - - 0.00 -6.48
Net Cash From Financing Activities		 0.00 19 3.23 15 16 107
Net Cash From Continuing Financing Activities		 0.00 19 3.23 15 16 107
Repurchase of Common Equity		 - 0.00 -0.11 -0.23 0.00 -0.14
Issuance of Common Equity		 0.00 19 2.91 16 16 107
Other Financing Activities, net		 - - 0.48 0.18 0.00 0.13
Effect of Exchange Rate Changes		 0.06 -0.01 -0.03 0.03 -0.00 0.00
Cash Interest Paid		 0.00 0.00 0.01 0.00 0.00 0.00
Cash Income Taxes Paid		 0.02 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Immix Biopharma

This table details how cash moves in and out of Immix Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 6.93 -2.07 12 -5.34 -4.28 -2.01 -1.76 -4.28 4.31 78 -15
Net Cash From Operating Activities		 -3.09 -2.68 -3.83 -5.26 -4.04 -1.48 -1.69 -5.31 -5.91 -11 -9.83
Net Cash From Continuing Operating Activities		 -3.09 -2.68 -3.83 -5.26 -4.04 -1.48 -1.69 -5.31 -5.91 -11 -9.83
Net Income / (Loss) Continuing Operations		 -4.34 -5.16 -5.33 -4.41 -7.15 -4.81 -4.54 -6.62 -7.59 -11 -10
Consolidated Net Income / (Loss)		 -4.34 -5.16 -5.33 -4.41 -7.15 -4.81 -4.54 -6.62 -7.59 -11 -10
Depreciation Expense		 0.00 0.00 0.00 0.00 0.01 0.02 0.04 0.06 0.10 0.05 0.09
Amortization Expense		 - - 0.02 0.02 0.02 0.02 0.02 0.02 0.04 0.04 0.04
Non-Cash Adjustments To Reconcile Net Income		 0.74 1.05 0.94 0.64 0.73 0.71 0.87 0.53 0.47 0.57 0.60
Changes in Operating Assets and Liabilities, net		 0.52 1.42 0.54 -1.51 2.35 2.59 1.93 0.70 1.07 -1.00 -0.47
Net Cash From Investing Activities		 -0.04 -0.01 -0.30 -0.10 -0.27 -0.51 -0.07 -0.13 -0.37 -6.65 -4.80
Net Cash From Continuing Investing Activities		 -0.04 -0.01 -0.30 -0.10 -0.27 -0.51 -0.07 -0.13 -0.37 -6.65 -4.80
Purchase of Property, Plant & Equipment		 -0.04 -0.01 -0.30 -0.10 -0.27 -0.51 -0.07 -0.13 -0.37 -0.17 -0.03
Purchase of Investments		 - - - - - - 0.00 - - - -7.77
Sale and/or Maturity of Investments		 - - - - - - 0.00 - - - 3.00
Net Cash From Financing Activities		 10 0.59 16 - - - 0.00 1.11 11 96 -0.04
Net Cash From Continuing Financing Activities		 10 0.59 16 - - - 0.00 1.11 11 96 -0.04
Repurchase of Common Equity		 -0.06 0.00 - - - - 0.00 - - 0.03 -0.07
Other Financing Activities, net		 - - - - - - 0.00 - - - 0.03
Effect of Exchange Rate Changes		 -0.01 0.03 -0.01 0.01 0.02 -0.03 -0.01 0.04 -0.02 -0.01 -0.01
Cash Income Taxes Paid		 0.01 -0.02 0.01 0.01 0.01 -0.03 0.01 0.01 0.01 -0.03 0.00

Annual Balance Sheets for Immix Biopharma

This table presents Immix Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.54 18 15 20 23 105
Total Current Assets		 0.53 18 15 20 20 101
Cash & Equivalents		 0.39 18 13 18 18 94
Short-Term Investments		 - - - - 0.00 6.48
Prepaid Expenses		 0.01 0.52 1.21 1.11 0.54 0.83
Plant, Property, & Equipment, net		 0.01 0.01 0.00 0.05 1.74 2.52
Total Noncurrent Assets		 0.00 0.00 0.01 0.09 1.01 1.08
Other Noncurrent Operating Assets		 - 0.00 0.01 0.09 1.01 1.08
Total Liabilities & Shareholders' Equity		 0.54 18 15 20 23 105
Total Liabilities		 5.27 0.20 1.75 3.72 9.70 11
Total Current Liabilities		 5.27 0.20 1.27 3.72 8.69 10
Accounts Payable		 0.25 0.14 1.27 3.72 8.62 9.97
Other Current Liabilities		 0.58 - - 0.00 0.07 0.14
Total Noncurrent Liabilities		 0.00 0.00 0.48 0.00 1.01 0.93
Capital Lease Obligations		 - - - - - 0.93
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -4.73 18 13 16 13 94
Total Preferred & Common Equity		 -4.73 18 13 16 13 94
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -4.73 18 13 16 13 94
Common Stock		 0.51 48 51 70 88 198
Retained Earnings		 -5.37 -30 -38 -53 -75 -104
Treasury Stock		 - 0.00 -0.10 -0.10 -0.10 -0.10
Accumulated Other Comprehensive Income / (Loss)		 0.13 0.13 0.09 0.13 -0.00 0.06

Quarterly Balance Sheets for Immix Biopharma

This table presents Immix Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 22 34 29 25 20 16 20 96
Total Current Assets		 22 33 27 23 17 12 17 92
Cash & Equivalents		 20 29 24 20 16 12 16 79
Short-Term Investments		 - - - - - - - 11
Prepaid Expenses		 2.10 1.57 1.38 1.09 0.86 0.69 0.64 1.70
Plant, Property, & Equipment, net		 0.04 0.36 0.45 1.36 2.12 2.23 2.36 2.43
Total Noncurrent Assets		 0.10 1.07 1.05 1.03 0.99 1.08 1.14 1.11
Other Noncurrent Operating Assets		 0.10 1.07 1.05 1.03 0.99 1.08 1.14 1.11
Total Liabilities & Shareholders' Equity		 22 34 29 25 20 16 20 96
Total Liabilities		 2.83 6.72 4.94 7.59 10 11 12 11
Total Current Liabilities		 2.83 5.66 3.90 6.56 9.31 10 11 11
Accounts Payable		 2.83 5.62 3.85 6.50 9.24 9.94 11 10
Other Current Liabilities		 - 0.03 0.05 0.06 0.07 0.07 0.14 0.13
Total Noncurrent Liabilities		 0.00 1.06 1.04 1.03 0.99 0.97 0.97 0.91
Capital Lease Obligations		 - 1.06 1.04 1.03 0.99 0.97 0.97 0.91
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 20 28 24 18 9.59 4.65 8.26 84
Total Preferred & Common Equity		 20 28 24 18 9.59 4.65 8.26 84
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 20 28 24 18 9.59 4.65 8.26 84
Common Stock		 68 87 87 88 89 91 102 199
Retained Earnings		 -48 -59 -63 -70 -80 -86 -94 -115
Treasury Stock		 -0.10 -0.10 -0.10 -0.10 -0.10 -0.10 -0.10 -0.10
Accumulated Other Comprehensive Income / (Loss)		 0.05 0.09 0.12 0.19 0.02 0.07 0.06 0.11

Annual Metrics And Ratios for Immix Biopharma

This table displays calculated financial ratios and metrics derived from Immix Biopharma's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 13,927,067.00 19,867,224.00 27,507,637.00 33,577,873.00
DEI Adjusted Shares Outstanding		 0.00 0.00 13,927,067.00 19,867,224.00 27,507,637.00 33,577,873.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.59 -0.78 -0.79 -0.88
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -1,312.71% 65.84% -96.37% -39.81% -31.17%
EBIT Growth		 0.00% -1,314.35% 65.91% -96.39% -40.48% -32.11%
NOPAT Growth		 0.00% -197.90% -507.90% -96.39% -40.48% -32.11%
Net Income Growth		 0.00% -2,024.28% 66.25% -89.50% -39.13% -35.67%
EPS Growth		 0.00% 0.00% 0.00% -50.85% 14.61% -17.11%
Operating Cash Flow Growth		 0.00% -292.72% -366.13% -53.50% -28.35% -63.96%
Free Cash Flow Firm Growth		 0.00% 0.00% -149.85% -102.48% -24.14% -54.70%
Invested Capital Growth		 0.00% 159.61% -168.43% -371.78% -239.15% -28.19%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -63.66% -10.85% 1.86% -24.68%
EBIT Q/Q Growth		 0.00% 0.00% -63.64% -10.86% 1.69% -24.56%
NOPAT Q/Q Growth		 0.00% 0.00% -63.64% -10.86% 1.69% -24.56%
Net Income Q/Q Growth		 0.00% 0.00% 69.73% -9.52% 1.56% -24.94%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 10.59% -17.11%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -60.41% 9.74% 7.60% -66.45%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 1.51% 14.81% -75.59%
Invested Capital Q/Q Growth		 0.00% 0.00% -64.89% -2,054.28% -297.96% 15.45%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 101.55% 100.02% 100.12% 100.17% 100.19% 100.13%
Interest Burden Percent		 66.30% 101.10% 100.01% 96.46% 95.51% 98.15%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 24.26% -367.80% -52.84% -106.23% -147.33% -55.00%
Cash Return on Invested Capital (CROIC)		 0.00% -501.62% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 24.26% -367.80% -52.84% -106.95% -148.34% -55.00%
Return on Equity Simple (ROE_SIMPLE)		 24.26% -135.54% -62.54% -95.07% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.32 -0.95 -5.75 -11 -16 -21
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 20.49% -346.36% -15.97% -27.77% -33.11% -14.46%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -69.73% -119.78% -22.14%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.70 -24 -8.22 -16 -23 -30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.70 -24 -8.22 -16 -23 -30
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.83 2.42 8.38 4.57 1.87
Price to Tangible Book Value (P/TBV)		 0.00 0.83 2.42 8.38 4.57 1.87
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 -0.87 0.00 0.00 0.00 0.00 0.01
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.01
Financial Leverage		 -0.86 -1.02 -1.00 -1.05 -1.19 -1.09
Leverage Ratio		 -0.11 1.41 1.06 1.19 1.46 1.19
Compound Leverage Factor		 -0.08 1.43 1.06 1.14 1.39 1.17
Debt to Total Capital		 -650.19% 0.28% 0.00% 0.00% 0.00% 0.99%
Short-Term Debt to Total Capital		 -650.19% 0.28% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.99%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% -1.25% 0.00% 0.00%
Common Equity to Total Capital		 750.19% 99.72% 100.00% 101.25% 100.00% 99.01%
Debt to EBITDA		 -2.41 0.00 0.00 0.00 0.00 -0.03
Net Debt to EBITDA		 -2.18 0.73 0.00 0.00 0.00 3.36
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.03
Debt to NOPAT		 -12.91 -0.05 0.00 0.00 0.00 -0.04
Net Debt to NOPAT		 -11.67 18.59 0.00 0.00 0.00 4.74
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.04
Altman Z-Score		 -32.51 38.93 6.66 16.71 -3.49 8.25
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% -0.69% -0.68% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.10 90.01 11.70 5.32 2.33 10.01
Quick Ratio		 0.07 87.33 10.55 4.70 2.04 9.93
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -2.03 -5.07 -10 -13 -20
Operating Cash Flow to CapEx		 0.00% -198,167.96% 0.00% -21,830.79% -1,239.31% -3,265.04%
Free Cash Flow to Firm to Interest Expense		 0.00 -7.63 -10,204.60 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -3.97 -5.97 -14,906.04 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -3.97 -5.98 -14,906.04 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.68 0.40 -0.28 -1.31 -4.43 -5.68
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.08 -0.68 -1.03 -3.12 -1.25
Enterprise Value (EV)		 25 -2.64 18 120 43 76
Market Capitalization		 21 15 32 137 61 176
Book Value per Share		 ($1.40) $4.90 $0.94 $0.83 $0.48 $2.79
Tangible Book Value per Share		 ($1.40) $4.90 $0.94 $0.83 $0.48 $2.79
Total Capital		 -0.63 18 13 16 13 95
Total Debt		 4.10 0.05 0.00 0.00 0.00 0.93
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.93
Net Debt		 3.71 -18 -13 -18 -18 -99
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.05 1.18 0.73
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.03 0.39 0.19 -1.44 -6.17 -9.28
Debt-free Net Working Capital (DFNWC)		 -0.64 18 14 16 12 91
Net Working Capital (NWC)		 -4.74 18 14 16 12 91
Net Nonoperating Expense (NNE)		 0.83 23 2.48 4.30 5.83 8.47
Net Nonoperating Obligations (NNO)		 4.05 -18 -13 -18 -18 -99
Total Depreciation and Amortization (D&A)		 0.00 0.06 0.00 0.01 0.12 0.36
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($6.64) ($0.59) ($0.89) ($0.76) ($0.89)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 13.86M 13.89M 17.34M 28.29M 32.97M
Adjusted Diluted Earnings per Share		 $0.00 ($6.64) $0.00 ($0.89) ($0.76) ($0.89)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 13.86M 13.90M 17.34M 28.29M 32.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($6.64) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.86M 13.90M 26.40M 27.72M 52.96M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.32 -0.95 -5.75 -11 -16 -21
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -16.72 -90.64 -16,537.12 0.00 0.00 0.00
NOPAT to Interest Expense		 -3.12 -3.56 -11,575.98 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -16.72 -90.64 -16,537.12 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -3.12 -3.56 -11,575.98 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -1.30% -1.50% 0.00% -0.47%

Quarterly Metrics And Ratios for Immix Biopharma

This table displays calculated financial ratios and metrics derived from Immix Biopharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 16,286,818.00 19,867,224.00 26,396,420.00 26,414,300.00 27,450,479.00 27,507,637.00 27,722,108.00 27,877,293.00 28,834,111.00 33,577,873.00 105,929,098.00
DEI Adjusted Shares Outstanding		 16,286,818.00 19,867,224.00 26,396,420.00 26,414,300.00 27,450,479.00 27,507,637.00 27,722,108.00 27,877,293.00 28,834,111.00 33,577,873.00 105,929,098.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.26 -0.26 -0.20 -0.17 -0.26 -0.17 -0.16 -0.24 -0.26 -0.32 -0.09
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -195.04% -41.61% -120.86% -25.75% -62.94% 7.95% 16.93% -41.89% -2.15% -118.42% -130.83%
EBIT Growth		 -195.02% -41.67% -121.76% -26.39% -63.47% 7.23% 16.23% -42.85% -3.62% -118.43% -130.71%
NOPAT Growth		 -195.02% -41.67% -121.76% -26.39% -63.47% 7.23% 16.23% -42.85% -3.62% -118.43% -130.71%
Net Income Growth		 -182.98% -35.67% -113.41% -22.45% -64.58% 6.66% 14.79% -50.31% -6.10% -122.11% -122.05%
EPS Growth		 -109.09% 0.00% -22.22% 37.50% -4.35% 37.50% 31.82% -46.67% 0.00% -86.67% -20.00%
Operating Cash Flow Growth		 -111.06% 31.42% -82.93% -49.52% -30.76% 44.87% 55.97% -1.02% -46.32% -647.16% -483.17%
Free Cash Flow Firm Growth		 -275.67% -38.44% -116.67% -9.39% -17.49% 86.59% 147.52% 160.78% 106.01% -1,639.12% -631.23%
Invested Capital Growth		 139.81% -371.78% -328.13% 85.46% -1,765.51% -239.15% -749.17% -727.01% -503.32% -28.19% 0.63%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -21.56% -18.80% -3.60% 15.95% -57.52% 32.88% 6.51% -43.56% -13.40% -43.51% 1.20%
EBIT Q/Q Growth		 -21.58% -18.84% -3.99% 15.88% -57.26% 32.56% 6.10% -43.45% -14.06% -42.16% 0.82%
NOPAT Q/Q Growth		 -21.58% -18.84% -3.99% 15.88% -57.26% 32.56% 6.10% -43.45% -14.06% -42.16% 0.82%
Net Income Q/Q Growth		 -20.72% -18.68% -3.41% 17.36% -62.27% 32.69% 5.60% -45.79% -14.54% -40.89% 5.62%
EPS Q/Q Growth		 4.17% -4.35% 8.33% 31.82% -60.00% 37.50% 0.00% -46.67% -9.09% -16.67% 35.71%
Operating Cash Flow Q/Q Growth		 12.19% 13.26% -42.93% -37.34% 23.21% 63.43% -14.15% -215.09% -11.22% -86.76% 10.90%
Free Cash Flow Firm Q/Q Growth		 0.34% 19.63% -10.08% -24.07% -7.03% 90.83% 490.01% 58.68% -89.42% -2,755.19% -19.13%
Invested Capital Q/Q Growth		 -87.07% -2,054.28% 51.90% 252.59% -216.11% -297.96% -20.44% -12.67% -11.72% 15.45% 6.64%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.16% 100.16% 100.17% 100.23% 100.16% 100.22% 100.22% 100.13% 100.10% 100.11% 100.00%
Interest Burden Percent		 95.87% 95.75% 95.21% 93.47% 96.53% 96.27% 96.79% 98.45% 98.90% 98.01% 93.36%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -78.25% -106.23% -93.62% -103.81% -118.50% -147.33% -112.34% -162.04% -182.55% -55.00% -74.47%
Cash Return on Invested Capital (CROIC)		 -15,597.35% 0.00% 0.00% -1,975.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -78.51% -106.95% -94.37% -103.97% -118.90% -148.34% -113.20% -162.04% -182.55% -55.00% -74.47%
Return on Equity Simple (ROE_SIMPLE)		 -72.01% 0.00% -66.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.17 -3.76 -3.91 -3.29 -5.18 -3.49 -3.28 -4.70 -5.36 -7.63 -7.56
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -6.45% -9.00% -7.14% -6.26% -10.32% -7.51% -5.86% -11.43% -13.21% -5.23% -4.83%
Return On Investment Capital (ROIC_SIMPLE)		 - -23.22% -13.64% -13.20% -27.86% -26.34% -30.97% -83.59% -58.11% -8.05% -8.87%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.52 -5.38 -5.59 -4.70 -7.39 -4.99 -4.68 -6.72 -7.66 -11 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.52 -5.37 -5.57 -4.68 -7.37 -4.95 -4.62 -6.64 -7.53 -11 -11
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.82 8.38 2.90 2.19 2.33 4.57 4.85 0.00 7.29 1.87 5.72
Price to Tangible Book Value (P/TBV)		 2.82 8.38 2.90 2.19 2.33 4.57 4.85 0.00 7.29 1.87 5.72
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 538.43 0.00 0.00 30.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.04 0.04 0.06 0.00 0.10 0.21 0.12 0.01 0.01
Long-Term Debt to Equity		 0.00 0.00 0.04 0.04 0.06 0.00 0.10 0.21 0.12 0.01 0.01
Financial Leverage		 -1.00 -1.05 -1.01 -0.96 -1.03 -1.19 -1.16 -1.18 -1.30 -1.09 -1.11
Leverage Ratio		 1.10 1.19 1.21 1.20 1.28 1.46 1.46 1.56 1.75 1.19 1.23
Compound Leverage Factor		 1.05 1.14 1.15 1.12 1.24 1.40 1.41 1.53 1.73 1.17 1.15
Debt to Total Capital		 0.00% 0.00% 3.69% 4.18% 5.52% 0.00% 9.36% 17.28% 10.46% 0.99% 1.07%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 3.69% 4.18% 5.52% 0.00% 9.36% 17.28% 10.46% 0.99% 1.07%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.63% -1.25% -0.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.63% 101.25% 97.30% 95.82% 94.48% 100.00% 90.64% 82.72% 89.54% 99.01% 98.93%
Debt to EBITDA		 0.00 0.00 -0.06 -0.05 -0.04 0.00 -0.05 -0.04 -0.04 -0.03 -0.03
Net Debt to EBITDA		 0.00 0.00 1.47 1.14 0.81 0.00 0.69 0.45 0.63 3.36 2.52
Long-Term Debt to EBITDA		 0.00 0.00 -0.06 -0.05 -0.04 0.00 -0.05 -0.04 -0.04 -0.03 -0.03
Debt to NOPAT		 0.00 0.00 -0.08 -0.07 -0.06 0.00 -0.07 -0.06 -0.06 -0.04 -0.04
Net Debt to NOPAT		 0.00 0.00 2.10 1.62 1.16 0.00 0.98 0.64 0.89 4.74 3.55
Long-Term Debt to NOPAT		 0.00 0.00 -0.08 -0.07 -0.06 0.00 -0.07 -0.06 -0.06 -0.04 -0.04
Altman Z-Score		 9.20 18.49 5.26 3.72 -0.87 -0.95 -3.21 0.00 -4.39 8.85 24.26
Noncontrolling Interest Sharing Ratio		 -0.34% -0.69% -0.80% -0.15% -0.34% -0.68% -0.76% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.90 5.32 5.82 7.00 3.47 2.33 1.80 1.23 1.53 10.01 8.76
Quick Ratio		 6.93 4.70 5.18 6.14 3.00 2.04 1.71 1.16 1.47 9.93 8.59
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.40 -2.73 -3.01 -3.73 -4.00 -0.37 1.43 2.27 0.24 -6.38 -7.60
Operating Cash Flow to CapEx		 -7,932.41% -20,319.02% -1,267.53% -5,414.40% -1,486.36% -291.08% -2,488.65% -4,160.29% -1,585.63% -6,679.51% -30,250.55%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.07 -1.31 -0.63 0.96 -1.11 -4.43 -5.34 -6.01 -6.72 -5.68 -5.30
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.23 -1.03 -0.90 0.44 -1.18 -3.12 -4.71 -6.97 -5.60 -1.25 0.03
Enterprise Value (EV)		 36 120 52 29 22 43 32 0.00 45 76 393
Market Capitalization		 56 137 81 52 41 61 47 0.00 60 176 483
Book Value per Share		 $1.21 $0.83 $1.06 $0.90 $0.64 $0.48 $0.35 $0.16 $0.29 $2.79 $1.59
Tangible Book Value per Share		 $1.21 $0.83 $1.06 $0.90 $0.64 $0.48 $0.35 $0.16 $0.29 $2.79 $1.59
Total Capital		 20 16 29 25 19 13 11 5.63 9.23 95 85
Total Debt		 0.00 0.00 1.06 1.04 1.03 0.00 0.99 0.97 0.97 0.93 0.91
Total Long-Term Debt		 0.00 0.00 1.06 1.04 1.03 0.00 0.99 0.97 0.97 0.93 0.91
Net Debt		 -20 -18 -28 -23 -19 -18 -15 -11 -15 -99 -90
Capital Expenditures (CapEx)		 0.04 0.01 0.30 0.10 0.27 0.51 0.07 0.13 0.37 0.17 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.08 -1.44 -2.06 -0.55 -3.50 -6.17 -8.45 -9.32 -10 -9.28 -8.84
Debt-free Net Working Capital (DFNWC)		 20 16 27 23 16 12 7.47 2.32 5.73 91 82
Net Working Capital (NWC)		 20 16 27 23 16 12 7.47 2.32 5.73 91 82
Net Nonoperating Expense (NNE)		 1.18 1.39 1.42 1.11 1.97 1.32 1.26 1.92 2.22 3.06 2.52
Net Nonoperating Obligations (NNO)		 -20 -18 -28 -23 -19 -18 -15 -11 -15 -99 -90
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.02 0.02 0.03 0.04 0.06 0.08 0.13 0.09 0.13
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.23) ($0.24) ($0.22) ($0.15) ($0.24) ($0.15) ($0.15) ($0.22) ($0.24) ($0.28) ($0.18)
Adjusted Weighted Average Basic Shares Outstanding		 18.58M 17.34M 23.44M 28.79M 29.42M 28.29M 29.70M 29.98M 31.93M 32.97M 55.37M
Adjusted Diluted Earnings per Share		 ($0.23) ($0.24) ($0.22) ($0.15) ($0.24) ($0.15) ($0.15) ($0.22) ($0.24) ($0.28) ($0.18)
Adjusted Weighted Average Diluted Shares Outstanding		 18.58M 17.34M 23.44M 28.79M 29.42M 28.29M 29.70M 29.98M 31.93M 32.97M 55.37M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 19.87M 26.40M 26.41M 27.45M 27.51M 27.72M 27.88M 28.83M 33.58M 52.96M 54.41M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.17 -3.76 -3.91 -3.29 -5.18 -3.49 -3.28 -4.70 -5.36 -7.63 -7.56
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -2.00% -1.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.71% -0.47% -0.59%

Financials Breakdown Chart

Key Financial Trends

Immix Biopharma’s latest quarter shows a company that is still very early-stage and heavily loss-making, but with a much stronger balance sheet than it had a year ago. Revenue remained $0, so the business is still funded primarily by cash and equity raises rather than commercial sales.

  • Cash position is much stronger than a year ago. Cash and equivalents were $79.3 million at Q1 2026, up sharply from $15.9 million in Q1 2025.
  • Total current assets are substantial. The company reported $92.3 million in current assets, giving it a large liquidity cushion for ongoing development work.
  • Equity improved meaningfully over the last year. Total common equity rose to $84.4 million from $9.6 million in Q1 2025, reflecting the capital it raised.
  • Interest and investment income helped offset losses. Q1 2026 interest and investment income was $717,168, up from $150,219 in Q1 2025.
  • Operating cash outflow improved versus the prior year. Cash used in operations was -$9.8 million in Q1 2026, better than -$11.0 million in Q4 2025.
  • R&D spending remains elevated. Research and development expense was $6.0 million in Q1 2026, broadly in line with prior quarters and consistent with an active clinical-stage company.
  • SG&A was also high. Selling, general and administrative expense came in at $4.8 million, suggesting overhead remains significant relative to the company’s size.
  • Stock-based or equity-related activity remains part of the story. The balance sheet and cash flow statements show recurring equity issuance and share count expansion over the past year.
  • There is still no revenue. Immix Biopharma reported $0 in revenue in Q1 2026, so it is not yet generating sales to support operations.
  • Losses remain large. Net loss was -$10.1 million in Q1 2026, only slightly improved from -$10.7 million in Q4 2025.

Looking at the broader trend, Immix Biopharma has consistently posted quarterly losses of roughly $4.3 million to $10.7 million over the last four years, with operating expenses rising as the company scaled its development efforts. The positive offset has been a stronger cash balance, helped by periodic capital raises, including a major financing in late 2025 that significantly boosted liquidity.

From a balance sheet perspective, the company appears well-capitalized for now, but investors should note that this strength depends on continued access to financing until the business can produce meaningful revenue. In short, IMMX looks financially liquid but still highly speculative, with execution in clinical development likely to matter more than near-term earnings.

07/15/26 11:00 AM ETAI Generated. May Contain Errors.

Immix Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Immix Biopharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Immix Biopharma's net income appears to be on an upward trend, with a most recent value of -$29.44 million in 2025, rising from -$1.15 million in 2020. The previous period was -$21.70 million in 2024. View Immix Biopharma's forecast to see where analysts expect Immix Biopharma to go next.

Immix Biopharma's total operating income in 2025 was -$29.96 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $29.96 million

Over the last 5 years, Immix Biopharma's total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Immix Biopharma's total liabilities were at $11.04 million at the end of 2025, a 13.9% increase from 2024, and a 109.6% increase since 2020.

In the past 5 years, Immix Biopharma's cash and equivalents has ranged from $391.09 thousand in 2020 to $93.93 million in 2025, and is currently $93.93 million as of their latest financial filing in 2025.

Over the last 5 years, Immix Biopharma's book value per share changed from -1.40 in 2020 to 2.79 in 2025, a change of -299.3%.


Related Companies

Financial statements for NASDAQ:IMMX last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel